NCT03965845: A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are not required to have a RAS-mutated solid tumor and are only eligible for Part 1
Exclusions: Patients with active untreated unstable central nervous system metastasis – see trial for details; Patients with prior treatment with CB-839 or palbociclib (Ibrance)

Comments are closed.

Up ↑